Media Articles Related to Keppra XR (Levetiracetam)
Seizure Control Key to Avoiding Sudden Death With Epilepsy
Source: MedicineNet Seizure Specialty [2017.04.26]
Title: Seizure Control Key to Avoiding Sudden Death With Epilepsy
Category: Health News
Created: 4/25/2017 12:00:00 AM
Last Editorial Review: 4/26/2017 12:00:00 AM
Cannabis compound may halve seizures for patients with severe epilepsy
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2017.04.19]
Cannabidiol - an active component of cannabis - more than halved the frequency of atonic seizures for patients with severe epilepsy, a new study reveals.
Pot Ingredient Might Ease Severe Epilepsy
Source: MedicineNet Seizure Specialty [2017.04.19]
Title: Pot Ingredient Might Ease Severe Epilepsy
Category: Health News
Created: 4/18/2017 12:00:00 AM
Last Editorial Review: 4/19/2017 12:00:00 AM
Study finds genetic basis for drug response in childhood absence epilepsy
Source: Epilepsy News From Medical News Today [2017.04.18]
Consider two children who have childhood absence epilepsy (CAE), the most common form of pediatric epilepsy.
Epilepsy: Another Potential Zika Threat to Babies
Source: MedicineNet Birth Defects Specialty [2017.04.18]
Title: Epilepsy: Another Potential Zika Threat to Babies
Category: Health News
Created: 4/17/2017 12:00:00 AM
Last Editorial Review: 4/18/2017 12:00:00 AM
Published Studies Related to Keppra XR (Levetiracetam)
Levetiracetam in the treatment of alcohol dependence: toward the end of the
that levetiracetam may be efficient in alcohol-related disorder... CONCLUSIONS: By conducting a state-of-the-art randomized-controlled clinical
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam
extended-release in very heavy drinking alcohol-dependent patients. 
population of very heavy drinkers... CONCLUSIONS: This multisite clinical trial showed no efficacy for levetiracetam
Double-masked, placebo-controlled study of intravenous levetiracetam for the
treatment of status epilepticus and acute repetitive seizures in dogs. 
BACKGROUND: Status epilepticus (SE) and acute repetitive seizures (ARS) are
common canine neurologic emergencies...
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. [2011.07]
BACKGROUND: This randomized double blind, placebo-controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease... CONCLUSIONS: Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties. (c) 2011 Movement Disorder Society. Copyright (c) 2011 Movement Disorder Society.
The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial. [2011.07]
Levetiracetam is an anticonvulsant which is assumed to act by modulating neurotransmitter release via binding to the vesicle protein SV2A. This could have an impact on signaling in the nociceptive system, and a pilot study indicated relief of neuropathic pain with levetiracetam. OBJECTIVES: The aim of this study was to test the analgesic effect of levetiracetam in painful polyneuropathy... CONCLUSION: This study indicates that the anticonvulsant levetiracetam has no clinically relevant effect on painful polyneuropathy. Copyright (c) 2010 European Federation of International Association for the Study of Pain Chapters. Published by Elsevier Ltd. All rights reserved.
Clinical Trials Related to Keppra XR (Levetiracetam)
Conversion to Monotherapy Study With Keppra XR for Partial Seizures [Completed]
The primary objective of this study is to assess the efficacy of two doses of Keppra XR
compared with a historical control as the placebo, in the monotherapy treatment of partial
IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures [Completed]
This study is looking at three seizure medicines. Patients with seizures are usually
treated with phenytoin (Dilantin) or Fosphenytoin. These medicines can be given
intravenously (IV)or by mouth. Another seizure medicine, levetiracetam (Keppra) can now be
given this way also. This study will compare IV phenytoin (Dilantin) and IV fosphenytoin to
levetiracetam (Keppra) in patients who have had a recent seizure. Only patients with a
history of seizures can be involved. The patient must present to the emergency department
within 4 hours of a seizure. The purpose of this study is to compare these three drugs,
phenytoin (Dilantin), fosphenytoin, and levetiracetam (Keppra). The investigators are
looking to see if these drugs can prevent another seizure in the next 24 hours. We are also
looking for any possible side effects.
Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures [Completed]
To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term
safety of Keppra XR in subjects with partial onset seizures.
Keppra for Cervical Dystonia [Suspended]
The purpose of this study is to evaluate if there is an improved response in CD symptoms
when Keppra is used as adjunctive therapy to Botox.
Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients [Completed]
Prospective randomized double blind controlled trial in prevention of relapse in recently
detoxified alcohol dependent patients with levetiracetam and placebo.
Reports of Suspected Keppra XR (Levetiracetam) Side Effects
Foetal Exposure During Pregnancy (19),
Upper Respiratory Tract Infection (10),
Premature Baby (10),
Inappropriate Schedule of Drug Administration (6),
Cerebrovascular Accident (6), more >>